Clinical exacerbation of SARS-CoV2 infection after fingolimod withdrawal.
J Med Virol
; 93(1): 546-549, 2021 01.
Article
em En
| MEDLINE
| ID: mdl-32644205
ABSTRACT
The role of disease-modifying therapies in patients with autoimmune disorders during severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) infection is controversial. Immunocompromised patients could have a more severe coronavirus disease-2019 (COVID-19) due to the absence of an adequate immune response against the SARS-CoV-2. However, therapies that act on immune response could play a protective role by dampening the cytokine-release syndrome. Fingolimod is a drug used for immune therapy in patients with multiple sclerosis (MS) through the sequestration of activated lymphocytes in the lymph nodes. We report the case of a 57-year-old man with relapsing-remitting MS treated with fingolimod that showed a reactivation of COVID-19 with signs of hyperinflammation syndrome after fingolimod withdrawal. Our case suggests that discontinuation of fingolimod during COVID-19 could imply a worsening of SARS-CoV2 infection.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Esclerose Múltipla Recidivante-Remitente
/
Cloridrato de Fingolimode
/
SARS-CoV-2
/
COVID-19
/
Imunossupressores
Limite:
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
J Med Virol
Ano de publicação:
2021
Tipo de documento:
Article